Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Alzamend Neuro, Inc.
Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
October 16, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
Tickers
ALZN
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
October 15, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
Tickers
ALZN
Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference
October 10, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
Tickers
ALZN
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder
August 19, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
Tickers
ALZN
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder
August 12, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
Tickers
ALZN
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder
August 06, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
Tickers
ALZN
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimer’s Disease
August 05, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
Tickers
ALZN
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
July 31, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
Tickers
ALZN
Alzamend Neuro Announces Reverse Stock Split
July 12, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
Tickers
ALZN
Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel
May 22, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
Tickers
ALZN
Alzamend Neuro Announces Initial Closing of Private Placement
May 14, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
Tickers
ALZN
Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million
May 09, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
Tickers
ALZN
Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program
May 07, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
Tickers
ALZN
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients
December 11, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Tickers
ALZN
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients
November 20, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Tickers
ALZN
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
November 16, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Tickers
ALZN
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001
November 13, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Tickers
ALZN
Alzamend Neuro Announces Reverse Stock Split
October 30, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Tickers
ALZN
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001
October 23, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Tickers
ALZN
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
October 02, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Tickers
ALZN
Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
April 03, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Tickers
ALZN
Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
March 22, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Tickers
ALZN
Alzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update
March 16, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Tickers
ALZN
Alzamend Neuro to Present at Sequire Biotechnology Conference
January 26, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Tickers
ALZN
Alzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/IIA Clinical Trial
January 04, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Tickers
ALZN
Alzamend Neuro Partners With the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for ALZN002 Phase I/IIA Immunotherapy Vaccine Clinical Trial to Treat Mild to Moderate Dementia of the Alzheimer’s Type
December 28, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
Tickers
ALZN
Alzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network to Discuss Therapeutic Pipeline
November 15, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
Tickers
ALZN
Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
October 31, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
Tickers
ALZN
Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’s Subjects
October 05, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
Tickers
ALZN
Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
September 29, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
Tickers
ALZN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.